Psoriasis
AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics
AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics
J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis
JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics
Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug
Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease
Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream
Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis
Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion
Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition
Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback
Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success
Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study
Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data
J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.